The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells (original) (raw)
References
Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42(4):253–260. doi:10.1016/j.dld.2009.12.008 ArticlePubMedCAS Google Scholar
Petrowsky H, Hong JC (2009) Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc 41(10):4023–4035. doi:10.1016/j.transproceed.2009.11.001 ArticlePubMedCAS Google Scholar
Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL (1996) Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224(4):463–473 (discussion 473–465) ArticlePubMedCAS Google Scholar
Anderson C, Kim R (2009) Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev 35(4):322–327. doi:10.1016/j.ctrv.2008.11.009 ArticlePubMed Google Scholar
Pratt WB, Morishima Y, Osawa Y (2008) The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 283(34):22885–22889. doi:10.1074/jbc.R800023200 ArticlePubMedCAS Google Scholar
Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, Parsons AB, Krogan N, Cagney G, Mai D, Greenblatt J, Boone C, Emili A, Houry WA (2005) Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120(5):715–727. doi:10.1016/j.cell.2004.12.024 ArticlePubMedCAS Google Scholar
McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, Frydman J (2007) Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131(1):121–135. doi:10.1016/j.cell.2007.07.036 ArticlePubMedCAS Google Scholar
Bagatell R, Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3(8):1021–1030 PubMedCAS Google Scholar
Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272(38):23843–23850 ArticlePubMedCAS Google Scholar
Gimenez Ortiz A, Montalar Salcedo J (2010) Heat shock proteins as targets in oncology. Clin Transl Oncol 12(3):166–173 ArticlePubMedCAS Google Scholar
Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM (2006) Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 12(22):6826–6835. doi:10.1158/1078-0432.CCR-06-1331 ArticlePubMedCAS Google Scholar
Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A (2006) Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin’s lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 12(2):584–590. doi:10.1158/1078-0432.CCR-05-1194 ArticlePubMedCAS Google Scholar
Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC (2010) Heat shock protein 90: inhibitors in clinical trials. J Med Chem 53(1):3–17. doi:10.1021/jm9004708 ArticlePubMedCAS Google Scholar
Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, Bacik J, Motzer RJ (2006) A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 24(6):543–546. doi:10.1007/s10637-006-9208-z ArticlePubMedCAS Google Scholar
Munster PN, Srethapakdi M, Moasser MM, Rosen N (2001) Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 61(7):2945–2952 PubMedCAS Google Scholar
Gossett DR, Bradley MS, Jin X, Lin J (2005) 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types. Gynecol Oncol 96(2):381–388. doi:10.1016/j.ygyno.2004.10.009 ArticlePubMedCAS Google Scholar
Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 6(3):1123–1132. doi:10.1158/1535-7163.MCT-06-0628 ArticlePubMedCAS Google Scholar
Watanabe G, Behrns KE, Kim JS, Kim RD (2009) Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis. Cancer Chemother Pharmacol 64(3):433–443. doi:10.1007/s00280-008-0888-2 ArticlePubMedCAS Google Scholar
Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J, Ekman S (2009) Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer 100(2):334–343. doi:10.1038/sj.bjc.6604855 ArticlePubMedCAS Google Scholar
Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM (2007) Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13(6):1783–1788. doi:10.1158/1078-0432.CCR-06-1892 ArticlePubMedCAS Google Scholar
Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11(9):3385–3391. doi:10.1158/1078-0432.CCR-04-2322 ArticlePubMedCAS Google Scholar
Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61(10):4003–4009 PubMedCAS Google Scholar
Burger AM, Fiebig HH, Stinson SF, Sausville EA (2004) 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15(4):377–387 ArticlePubMedCAS Google Scholar
Burlacu A (2003) Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 7(3):249–257 ArticlePubMedCAS Google Scholar
Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, He B, Jablons DM (2008) Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 3(10):1089–1095. doi:10.1097/JTO.0b013e3181839693 ArticlePubMed Google Scholar